Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,332.00
Bid: 12,344.00
Ask: 12,346.00
Change: 68.00 (0.55%)
Spread: 2.00 (0.016%)
Open: 12,268.00
High: 12,388.00
Low: 12,256.00
Prev. Close: 12,264.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: Miners Weigh On FTSE 100 Ahead Of US Nonfarm Payrolls

Fri, 06th Mar 2015 10:46

LONDON (Alliance News) - The FTSE 100 is trading lower mid-morning Friday, weighed upon by the mining sector, which has been dragged down by weak commodity prices as investors look ahead to the highly anticipated US nonfarm payrolls report.

The FTSE 100, which is heavily weighted in mining and resource stocks, is down 0.2% at 6,948.79, while the FTSE 250 is up 0.2% at 17,347.35, and the AIM All-Share is up 0.3% at 716.31.

In Europe, the French CAC 40 is down 0.2%, and the German DAX 30 is flat.

Fresnillo, down 2.5%, and Randgold Resources, down 1.9%, are the two biggest fallers in the FTSE 100 as gold prices continue to decline. The precious metal has fallen for the last four days and continues its negative trend, trading at USD1,194.53 an ounce.

Anglo American, down 1.5%, and Rio Tinto, down 0.7%, also are amongst the biggest fallers in the index after an Australian media report that iron ore prices fell to a fresh six-year low of USD59.30 a tonne. Rio also said Friday that it has increased its reserves in the Diavik diamond project, the Pilbara iron project and the Hail Creek Coal project.

Outside of mining, AstraZeneca, down 1.2%, also is one of the biggest fallers in the blue-chip index. The pharmaceutical giant guided that it expects its total revenue to decline by a mid-single digit percentage at constant exchange rates in 2015, in line with previous sales revenue guidance it gave at the time of its full-year results, as it announced changes to the way it presents its revenue. AstraZeneca maintained its core earnings per share guidance.

Shares in Weir Group lead FTSE 100 gainers, up 5.6% on press reports that the oil and gas service company could have attracted a bid from a US private equity firm. The Independent reports that GE Capital is linked with making a 2,800.00 pence per share bid, though it does attribute this to "starry-eyed punters". The stock is quoted at 1,830.36p.

Thomas Cook is the biggest gainer in the FTSE 250, up 19%. The travel operator said it has struck a strategic deal with Chinese investment group Fosun International Ltd under which the latter will acquire a 5% stake in the company. Thomas Cook said Fosun will pay GBP91.8 million to acquire 73.1 million shares Thomas Cook will issue to it, giving Fosun a 5% stake in the company. The shares are valued at 125.58 pence, compared to the travel firm's closing price Thursday of 120.60p. The stock currently trades at 143.90p.

Afren is the second-best performer in the index up 12%. The troubled oil and gas company, which will be relegated from the FTSE 250 on March 23, is looking to China to bring in "substantial" new capital, in the form of new equity, the Financial Times reported. Ethelbert Cooper, the Liberian entrepreneur who founded Afren, plans to recapitalize the company in partnership with a consortium of Chinese investors. This will become the first Africa-China partnership in the oil and gas sector listed in the UK.

Fourth quarter eurozone GDP met expectations to show quarter-on-quarter growth of 0.9%. The figure was a slight improvement on the third quarter reading of 0.8%. The year-on-year figure also matched estimates of a 0.3% growth, marginally higher than the 0.2% shown in the third quarter.

The euro had already fallen to a new 11-year low against the dollar ahead of the GDP results and continued lower afterward. The currency has reached a low Friday of USD1.0961.

The median expectations for UK inflation for the coming year was 1.9% in February compared to 2.5% in November, according to a survey from the Bank of England. This was its lowest level in more than 13 years. UK inflation had fallen to a record low 0.3% in January, dragged by falling motor fuel and food prices.

Still ahead in the economic calendar are the crucial US nonfarm payrolls, unemployment rate and average earnings figures, due at 1330 GMT.

By Neil Thakrar; neilthakrar@alliancenews.com; @NeilThakrar1

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
1 Dec 2023 08:33

AstraZeneca discontinues two phase III evidence trials for Lokelma

(Alliance News) - AstraZeneca on Friday said it has decided to discontinue the Stabilize-CKD and Dialize-outcomes phase III trials for Lokelma, citing increased enrolment timelines.

Read more
1 Dec 2023 08:01

AstraZeneca calls off two phase III trials into hyperkalaemia treatment

(Sharecast News) - Drugmaker AstraZeneca has called off two phase III trials on its hyperkalaemia treatment after a series of logistical challenges.

Read more
1 Dec 2023 07:41

LONDON BRIEFING: Stocks called higher; UK house prices fall annually

(Alliance News) - Stocks in London are called to open higher on Friday, following data from Nationwide showing that the annual pace of UK house price decline slowed in November.

Read more
27 Nov 2023 16:12

London close: Stocks start week in subdued state

(Sharecast News) - London's financial markets saw a somewhat subdued performance on Monday, as concerns regarding the Chinese economy cast a shadow over investor sentiment.

Read more
27 Nov 2023 09:20

LONDON BROKER RATINGS: Peel, Numis up Rightmove; Goldman cuts Entain

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
23 Nov 2023 18:41

IN BRIEF: AstraZeneca Chair Demare buys shares for over GBP200,000

AstraZeneca PLC - Cambridge-based pharmaceutical company - Chair Michel Demare buys 2,000 shares in total on Wednesday and Tuesday. Buys 1,000 shares for GBP101.05 each on Tuesday and 1,000 shares for GBP101.70 each on Thursday, for a total of GBP202,752.

Read more
20 Nov 2023 10:49

AstraZeneca launches new life sciences tech innovation firm Evinova

(Alliance News) - AstraZeneca PLC on Monday launched Evinova, a new health technology business focused on accelerating innovation across the life sciences sector, delivery of clinical trials and better health outcomes.

Read more
17 Nov 2023 15:20

London close: Stocks higher despite weaker retail sales data

(Sharecast News) - London's stock markets finished in a positive state on Friday despite weaker-than-expected UK retail sales figures.

Read more
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.